The Food and Drug Administration has accepted a regulatory approval application from Takeda and Lundbeck for an experimental drug to treat depression, the companies said Wednesday.

Eli Lilly announced that it has met Food and Drug Administration requirements for pediatric exclusivity for its antidepressant medication.

Women take mental health drugs at a much higher rate than men, according to a new study by one of the country's largest pharmacy benefit managers.

GlaxoSmithKline can sell an authorized generic of its antidepressant drug to Toronto-based drug maker Apotex, a U.S. judge ruled.

AstraZeneca and Targacept released results of the second of four phase-3 clinical trials that investigated the efficacy and tolerability of a drug that could serve as an adjunct therapy to major depressive disorder patients that had an inadequate response to initial antidepressant therapies.

AstraZeneca and Targacept released results of the first of four phase-3 clinical trials that investigated the efficacy and tolerability of a drug that could serve as an adjunct therapy to major depressive disorder patients that had an inadequate response to initial antidepressant therapies.

The Food and Drug Administration has approved a new strength for a psychiatric drug made by Edgemont Pharmaceuticals, Edgemont said Tuesday.

Patients taking an investigative antidepressant undergoing late-stage clinical development showed “significant” improvement, according to study results released Monday.

Pharmacy benefit manager Medco’s research arm is teaming up with personalized medicine and pharmacogenetics company AssureRx Health in a pilot program to evaluate adherence and medical care utilization among patients taking antidepressants and antipsychotics.

Patients who take generic antidepressants will remain as adherent as those who take brand-name drugs to treat the condition, according to a new study.

British drug maker GlaxoSmithKline will pay nearly $1 billion to the U.S. government to settle...